Outcome reporting in industry-sponsored trials of gabapentin for off-label use
about
Reporting bias in medical research - a narrative reviewGabapentin for fibromyalgia pain in adultsBias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventionsGabapentin for chronic neuropathic pain and fibromyalgia in adultsWhy the Cochrane Risk of Bias Tool Should Include Funding Source as a Standard ItemGabapentin or pregabalin for the prophylaxis of episodic migraine in adultsIndustry sponsorship and research outcomeComparison of protocols and registry entries to published reports for randomised controlled trialsGabapentin for chronic neuropathic pain and fibromyalgia in adultsOutcome reporting among drug trials registered in ClinicalTrials.govPublication and other reporting biases in cognitive sciences: detection, prevalence, and prevention.Patient-reported outcomes as a source of evidence in off-label prescribing: analysis of data from PatientsLikeMeMultiplicity of data in trial reports and the reliability of meta-analyses: empirical studyReboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trialsWhy Most Clinical Research Is Not UsefulRandomised trials in context: practical problems and social aspects of evidence-based medicine and policyFrom Protocols to Publications: A Study in Selective Reporting of Outcomes in Randomized Trials in OncologySystematic review of the empirical evidence of study publication bias and outcome reporting bias - an updated reviewInadequate use and regulation of interventions against publication bias decreases their effectiveness: a systematic reviewPublication bias in laboratory animal research: a survey on magnitude, drivers, consequences and potential solutionsImplementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin® litigationComparative effectiveness research: an empirical study of trials registered in ClinicalTrials.govImpact of reporting bias in network meta-analysis of antidepressant placebo-controlled trialsDifferences in reporting of analyses in internal company documents versus published trial reports: comparisons in industry-sponsored trials in off-label uses of gabapentinPatented drug extension strategies on healthcare spending: a cost-evaluation analysisCompleteness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available dataIntegrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic reviewIncreasing value and reducing waste: addressing inaccessible researchWho has used internal company documents for biomedical and public health research and where did they find them?Strategies for obtaining unpublished drug trial data: a qualitative interview studySPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trialsResults and outcome reporting In ClinicalTrials.gov, what makes it happen?Why we need easy access to all data from all clinical trials and how to accomplish itThe financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.The ClinicalTrials.gov results database--update and key issuesPeginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.What comparative effectiveness research is needed? A framework for using guidelines and systematic reviews to identify evidence gaps and research priorities.Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reportsThe 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines.How transparent are migraine clinical trials? Repository of Registered Migraine Trials (RReMiT).
P2860
Q21203744-3203C513-5ADB-4FD3-A68D-7C88B012AC9CQ24185818-38F4C829-6B9D-4B1D-B4B5-489B20536791Q24193207-B51448EC-7E7D-4836-8523-0119AFCF05D2Q24194998-AA0BB93B-1E3F-4B89-9504-F2337FE76023Q24201550-99AE9278-9398-4808-BC16-C73C7B92E058Q24201830-2C4A3755-2A39-4F29-BA12-45A4B8A01CF5Q24202591-0CCEC2CF-3F82-43B9-975B-2BBF7BE17A45Q24235035-F91E8305-1733-4B04-B14A-9540BB14711DQ24235709-42F4294D-97DD-48C4-B97D-B0E687B6D4E5Q24289273-3DDF36EC-D52B-4557-A981-7FE9836DEC2AQ24289398-A1BC6D5B-7D6C-4631-9B4C-94DD6D450353Q24595345-E5D95DF1-7E56-4876-95DD-C999D83CE53BQ24597537-0CF17003-A200-44FA-BBF4-C2372EEAB3F7Q24632255-C62F3F7D-A105-46F1-9FB6-8C4A28220533Q24707972-B95098E6-8FFD-4BAE-BAFD-67F7295A026CQ26784106-57BF942E-FA9C-4944-83F8-744A4EC8BCEBQ26797522-DECA38D8-4CCC-4C26-A0FF-2AB0C071385DQ26851424-254B4E37-DCA2-442D-9238-1AB5D4BFAAD7Q26995526-0CC8D6FA-00BC-461B-9A8C-BCD14DC8E79EQ27323022-4531B31D-2DE0-4FFA-A045-DEC2106C4CC4Q27498844-BCB56EA3-8073-4ABC-AFCA-69D29A087A58Q28478742-0B0E5B97-D507-4945-8250-976A8ACE3525Q28482475-146CDA93-408C-4B32-9CF3-E740FACC2D2BQ28485343-D7BC04C8-54A0-406F-ABEB-E193B24BC839Q28533630-8FB2E55F-63F2-403D-98EC-F3DE2BCEE976Q28534273-461FF332-2F38-4132-89A8-75E3F46E8D56Q28608153-157C7225-C65D-4117-9045-1C7DEF89B652Q28611347-3707E33F-43C0-47A6-BCA7-E916D80BA270Q28657906-AECF9210-DAA9-4F5A-AAD5-B25877DA5680Q28681320-54D7ACA4-7C81-4D4B-9087-B79913DCC53FQ28710019-2190A9E8-D9B3-49E7-9C6B-E52E721A9454Q28728487-2F87F347-481F-4B04-93B0-8B0C2178F915Q28732492-27154B62-B06E-4B74-8C6C-AEFABB9A7AF6Q33583631-60AF8F93-4BDF-4805-BF47-785AFC079AE7Q33834724-F2A7E465-6A09-42FF-B610-024887A968FEQ34100819-DFCD55DC-C0BD-4EF8-8036-918FEDD8CFF9Q34258967-0F16A2BE-4E1D-43BB-9DDE-E16FBDC45062Q34264254-FC760CE7-83BA-40CD-AD52-036627DAB1E7Q34279280-123E008B-005E-4B58-BD6F-BCD54BE54D42Q34303798-E77A8845-5DEC-4C99-9D47-B08D11A283D9
P2860
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@ast
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@en
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@nl
type
label
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@ast
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@en
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@nl
prefLabel
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@ast
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@en
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@nl
P3181
P356
P1476
Outcome reporting in industry-sponsored trials of gabapentin for off-label use
@en
P2093
Roberta W Scherer
S Swaroop Vedula
P304
P3181
P356
10.1056/NEJMSA0906126
P407
P577
2009-11-12T00:00:00Z